大鼠化学诱导性结肠炎模型的建立及云母干预治疗机制探讨
|
摘要
溃疡性结肠炎(Ulcerative Colitis,UC)主要临床表现为反复发作的腹痛、腹泻、粘液脓血便等,病变多累及直肠和乙状结肠。UC在欧美国家发病率高,我国的发病率正急剧上升。由于UC病因不明且治疗困难,给社会生产力和个人生活质量带来极大影响,引起了各国高度重视,是当今国际消化病诊治研究的热点。
有报道显示在我国70.2%UC患者为局限性的直肠乙状结肠炎,对该类患者的治疗主要以灌肠为主。灌肠可以使药物直接和病变部位接触并减少药物的全身副作用。目前用于灌肠的药物主要有5-氨基水杨酸(5-Aminosalicylic Acid,5-ASA)和各种糖皮质激素,但5-ASA价格昂贵,且目前国内还未开发灌肠剂型;糖皮质激素灌肠后仍有较多患者出现全身副作用,研究高效安全且价格合适的灌肠成品有极大的意义。
云母是硅酸盐类矿物药之一,古代医家认为云母有“生肌敛疮”、“补中”、“主下痢”等功用,其药用价值在我国历史悠久,很可能云母灌肠对UC有效。
选择和建立合适的动物模型是研究UC药物治疗不可缺少的重要方法。UC的动物模型虽然有众多研究,但至今尚不理想。化学诱导性结肠炎是比较广泛采用的UC模型,包括葡聚糖硫酸钠(Dextran Sulfate soduium,DSS)及2,4,6-三硝基苯磺酸(Trinitrobenzene Sulfonic Acid,TNBS)诱导性结肠炎模型。DSS诱导性结肠炎主要在结肠远端,其病理表现符合UC的特点,但是这个模型的一个很大的障碍是DSS非常昂贵。TNBS诱导性结肠炎模型是一种经典的炎症性肠病模型,诱导后产生的远端结肠病变持续存在,有许多学者把TNBS诱导性结肠炎模型作为UC的模型。
为了验证云母灌肠对结肠炎的治疗作用,我们首先建立起两种动物模型并对其疗效进行双重验证。我们重复了经典的TNBS诱导性结肠炎,并尝试建立了一种新的复合型大鼠DSS/乙醇化学诱导性结肠炎模型。将雌性SD大鼠随机分为4组,A组为模型组,B组和C组为阳性对照组,D组为正常对照组。A组和B组的大鼠自由饮用2%DSS 3天,C组和D组的大鼠自由饮用消毒后的自来水3天。第4天,A组和B组的大鼠分别灌肠内注入0.5ml 30%乙醇或生理盐水,C组和D组分别结肠内灌注0.5ml 30%乙醇或生理盐水。各组进行疾病活动指数的评分,同时在结肠注入乙醇或生理盐水后24小时、3天、7天、14天和21天随机处死每组大鼠各5只进行大体评分和病理评分;结果显示模型组大鼠自由饮用2%DSS 3天后灌肠注入30%乙醇可以诱导出现类似UC的体重下降、腹泻和血便。大体可见远端结肠有溃疡和炎症,病理显示炎症细胞侵润、隐窝脓肿和异型增生等UC的的病理特点。和正常对照组相比,模型组大鼠的体重明显减少,结肠的大体和病理积分增加;该模型和人类UC具有类似的临床和形态特点,且相对价格便宜、制作简单。
我们先以云母灌肠治疗大鼠DSS/乙醇化学诱导性结肠炎来确认云母的治疗作用。正常对照组、DSS/乙醇模型组、云母治疗组、5-ASA治疗组在制模的当天开始灌肠用药,连续用药10天。观察治疗前后大鼠体重的改变和治疗后大鼠结肠的大体和病理积分。云母或5-ASA灌肠治疗DSS/乙醇结肠炎后大鼠体重减少的情况有明显改善,同时大体积分明显减少,病理积分也同样明显减少。通过该部分研究明确了云母灌肠治疗DSS/乙醇化学诱导性结肠炎有效。
然后进一步在TNBS诱导性结肠炎模型上进行量效研究。TNBS诱导性结肠炎模型建立的当天分别给予低剂量云母(240mg/kg/d)、中剂量云母(480mg/kg/d)、高剂量云母(960mg/kg/d)和5-ASA(360mg/kg/d)灌肠。用药14天后,比较大鼠治疗前后体重改变情况和结肠的大体、病理积分;结肠灌注不同剂量的云母可以剂量相关地改善TNBS诱导性结肠炎大鼠的体重减少现象,同时减少大鼠结肠的大体和病理积分。该部分研究提示云母治疗结肠炎有量效关系。
为了进一步探讨云母起效的可能机制,我们接着对云母作用的体内和体外机制进行深入的研究。过度的免疫反应是UC炎症和组织损伤的内在重要因素,而细胞因子在调节肠道免疫反应中扮演重要角色,与UC的发生及转归密切相关。与UC发病有关的细胞因子主要有TNF-a(Tumor Necrosis Factor-α,TNF-α)、IL-1β(Interleukin-1β,IL-1β)、IL-8等。我们采用大鼠TNBS诱导性结肠炎模型在体内水平深入研究了云母灌肠治疗后大鼠结肠局部TNF-α、IL-1β的基因和蛋白的改变情况。TNBS大鼠结肠炎模型制模的当天随机分组,分别给予低剂量云母、中剂量云母、高剂量云母和5-ASA灌肠。用药14天后,PT-PCR检测结肠组织中TNF-α、IL-1β、粘蛋白2(Mucin 2,MUC2)和肠三叶因子(Intestinal Trefoil Factor,ITF)的mRNA含量。ELISA方法检测结肠组织中TNF-α、IL-1β蛋白含量,免疫组化和AB-PAS(Alcian blue/periodic acid-Schiff reaction)染色检测粘蛋白分布情况。结果显示TNBS诱导性结肠炎大鼠的结肠组织中TNF-α、IL-1β的mRNA和蛋白水平均明显增加,云母和5-ASA灌肠可以减少结肠炎大鼠结肠中TNF-α、IL-1β的mRNA和蛋白量。同时还发现TNBS诱导性结肠炎大鼠结肠中MUC2 mRNA明显下降,云母和5-ASA灌肠治疗后有所上升。但是,各组结肠中ITF mRNA无明显改变。该部分研究提示云母灌肠治疗可以明显降低TNBS诱导性结肠炎局部的TNF-α、IL-1β的mRNA和蛋白水平。
最后采用THP-1和HT-29两种细胞株TNF-α、IL-1β和IL-8三种细胞因子的标准品在体外研究了云母对这三种细胞因子的作用情况。ELISA方法检测云母对脂多糖(Lipopolysaccharide,LPS)刺激后的THP-1和HT-29两种细胞株分泌的细胞因子TNF-α、IL-1β及IL-8的影响情况。ELISA方法检测不同剂量的云母和TNF-α、IL-1β及IL-8三种标准品共同孵育1小时后这三种细胞因子的变化情况。结果显示云母可以剂量依赖性地减少THP-1细胞株分泌的TNF-α、IL-1β和HT-29细胞株分泌的IL-8蛋白含量。TNF-α、IL-1β及IL-8这三种细胞因子的标准品在和云母共同孵育1小时后都有明显的剂量依赖性的下降。
通过上述实验,我们成功建立一种新的符合人类UC的大鼠化学诱导性结肠炎模型;明确了云母灌肠对两种化学诱导性结肠炎的治疗作用并摸索出量效关系。云母治疗作用机制与降低肠道局部的TNF-α、IL-1β的mRNA和蛋白有关,云母能吸附肠道各种细胞所释放的细胞因子可能是其起效的机制之一。
Ulcerative colitis(UC) is an inflammatory disease of unknown cause that exhibits a clinical course with remission and exacerbations,characterized by abdominal pain, rectal bleeding and diarrhea.Inflammation usually occurs in the rectum and lower part of the colon.The number of cases increased rapidly in China.With long term of bowel symptoms and systemic symptoms,the quality of life and social function of patients are also affected severely.The research of UC is a hot topic nowadays.
One study showed 70.2%were proctosigmoiditis or proctitis.For the treatment of UC confined to the rectum and sigmoid,topical administration of medicines,such as glucocorticoids and 5-aminosalicylic acid(5-ASA),to the injured colonic mucosa has been shown to be more effective and less hazardous than systemic administration. However,current topical treatments for UC have their limitations.For example,the high price of 5-ASA prevents it to be wildly used in our country.When applying glucocorticoids topically,there is still a significant absorption of glucocorticoids through the inflamed mucosa that causes systemic effects.It is necessary to develop alternative therapeutic approaches that are effective,affordable and have less adverse effects.
Muscovite is one kind of natural clay consisting of an insoluble double silicate of aluminium and magnesium.In traditional Chinese medicine it has been documented that muscovite has antidiarrheal activity and can protect mucosa.It's possible that rectal administration of muscovite can alleviate inflammation of UC.
Adequate animal model of UC is a useful tool of research on the therapeutic agents.Several models of experimental colitis resembling ulcerative colitis have been reported previously.The most widely used models are induced by administering toxic chemical such as dextran sulfate sodium(DSS),trinitrobenzene sulfonic acid(TNBS). However,DSS-induced colitis results in inflammation mainly in the distal colonic mucosa.The histopathology of this model showed some characteristics resemblance to UC,enabling research into the pathogenesis and therapy of this disease.But an obvious obstacle with regard to the DSS model is that DSS is very expensive.Thus it is difficulty to apply this model widely in some regions.TNBS-induced colitis is a traditional model of inflammatory bowel disease and is widely used.
In order to investigate whether rectal administration of muscovite can alleviate inflammation of UC,we established two animal models of UC to doublely check its effect.Besides TNBS-induced colitis,we developed an inexpensive DSS/ethanol model of UC rats.Female rats were randomized into four groups.In group A and B rats received 2%dextran sulfate sodium in the drinking water for 3 days.On day 4,rats in group A and B received 0.5ml 30%ethanol or saline intracolonically respectively.As a control,rats in group C and D only received intracolonic 30%ethanol or saline respectively.Before enema,the rats were lightly anesthetized with ether.30%ethanol or saline was instilled into the lumen of the colon through the rubber catheter.Disease Activity Index(DAI) was used to quantify the clinical evolution of every group.At various times(24h,3 th day,7th day,14 th day and 21 th day) after intracolonic administration of 30%ethanol or control saline,5 rats from each treatment group were randomly selected and killed to assess for colonic inflammatory and ulcerative responses with respect to gross morphologic damage and histopathologic scoring system.The results showed the DSS/ethanol induced significant weight loss,diarrhea and hematochezia in rats.Ulcerations and inflammation of the distal part of rat colon were developed rapidly.Histological examination showed an increased infiltration of polymorphonuclear leukocytes,lymphocytes and existence of cryptic abscesses and dysplasia.The weight of rat with colitis was decreased while the gross morphologic and histopathologic scores were increased.The successfully established DSS/ethanol model is characterized by a clinical course,localization of the lesions and histopathological features similar to human UC while it is much cheaper than DSS model.
First we examined the effect of rectal administration of muscovite on DSS/ethanol induced colitis.The experimental animals were randomly divided into 4 groups to take the rectal administration of muscovite,5-ASA and the equal amount of control respectively from beginning of the induction of the colitis rats to the end of study while another group was administrated rectally with only saline served as normal control. After 10 days of treatment,the animals were assessed for colonic inflammatory and ulcerative responses with respect to change of body weight,gross morphologic damage and histopathologic scoring system.The results showed the loss of weight in the colitis groups was significantly higher than that of normal group(P＜0.01).Rectal administration of muscovite improved the loss of body weight of DSS/ethanol induced colitis.Treatment of rats with muscovite or 5-ASA decreased both morphologic and histopathologic scores of DSS/ethanol induced rats.This part showed that rectal administration of muscovite could ameliorate colonic inflammation of DSS/ethanol induced colitis.
Then we examined the effect of administration of different dosage of muscovite on TNBS-induced colitis in rats.Female SD rats with TNBS-induced colitis were treated with rectal administration of different dosage of muscovite daily for 14 days.The changes in body weight,macroscopic damage and histologic scores were subsequently evaluated.The effect of muscovite was compared with that of 5-ASA.We found rectal administration of muscovite improved the loss of body weight,macroscopic and histologic scores of TNBS-induced colitis in a dose-dependent manner.This part showed that rectal administration of different dosage of muscovite could ameliorate colonic inflammation of TNBS-induced colitis.
Based on these observations we proved that muscovite is useful for the treatment of these two kinds of colitis.Further experiments were also done to ascertain the possible mechanisms involved in the anti-inflammtory effect of muscovite.An exaggerated intestinal immune response in colon plays a key role in the pathophysiology of UC.Pathological processes accompanying UC are associated with aberrant expression of many proinflammatory cytokines,including tumor necrosis factor-α(TNF-α),Interleukin-1β(IL-1β) and IL-8.To ascertain the possible mechanisms involoed in the anti-inflammtory effect of muscovite,we examined the effect of muscovite on the mucosal inflammatory changes by studying the expression of IL-1βand TNF-αin the colonic tissues in rats with TNBS-induced colitis.Female SD rats with TNBS-induced colitis were treated with rectal administration of different dosage of muscovite daily for 14 days.Gene expression of TNF-α,IL-1β,mucin2 (MUC2) and intestinal trefoil factor(ITF) in the colonic tissues was assessed by semiquantitative reverse-transcription polymerase chain reaction(RT-PCR) while protein levels of TNF-αand IL-1βwere detected by enzyme-linked immunosorbent assay(ELISA).MUC2 expression in colonic mucosa was detected by immunohistochemistry and Alcian blue-periodic acid Schiff(AB-PAS).The results showed TNBS-induced expression of TNF-α,IL-1βwas reduced by administration of muscovite and 5-ASA.Reduction of MUC2 expression in colitis rats was reversed by muscovite and 5-ASA treatment.However,the expression of ITF mRNA in colonic mucosa was not affected.This part showed rectal administration of different dosage of muscovite can decrease the expression of TNF-α,IL-1β.
In the end,the capacity of muscovite to adsorb cytokines in vitro was determine by measuring the residual amount of standard TNF-α,IL-1βand IL-8 after these cytokines were incubated with muscovite for 1 hours as well as the changes in the amount of TNF-α,IL-1βsecreted by lipopolysaccharide(LPS)-stimulated THP-1 cells and IL-8 secreted by LPS- stimulated HT-29 cells.Muscovite inhibited the expression of TNF-α, IL-1βsecreted by THP-1 and IL-8 secreted by HT-29 cells in a dose-dependent manner. The levels of standard TNF-α,IL-1βand IL-8 were also decreased dramatically after incubating with muscovite for 1 hour.
In conclusion,we successfully established a model of chemincal-induced experimental colitis which is characterized by a clinical course,localization of the lesions and histopathological features similar to human UC.We confirmed that rectal administration of muscovite can ameliorate colonic inflammation of two different kinds of chemical-induced experimental colitis and can ameliorate colonic inflammation of TNBS-induced colitis in dose-depend manner.The mechanism of therapeutic effect of muscovite is related with the fact that rectal administration of different dosage of muscovite can decrease the mRNA and protein expression of TNF-α,IL-1β.The possible mechanisms of muscovite include a direct adsorptive action of cytokines production by mucosal cells.
有报道显示在我国70.2%UC患者为局限性的直肠乙状结肠炎,对该类患者的治疗主要以灌肠为主。灌肠可以使药物直接和病变部位接触并减少药物的全身副作用。目前用于灌肠的药物主要有5-氨基水杨酸(5-Aminosalicylic Acid,5-ASA)和各种糖皮质激素,但5-ASA价格昂贵,且目前国内还未开发灌肠剂型;糖皮质激素灌肠后仍有较多患者出现全身副作用,研究高效安全且价格合适的灌肠成品有极大的意义。
云母是硅酸盐类矿物药之一,古代医家认为云母有“生肌敛疮”、“补中”、“主下痢”等功用,其药用价值在我国历史悠久,很可能云母灌肠对UC有效。
选择和建立合适的动物模型是研究UC药物治疗不可缺少的重要方法。UC的动物模型虽然有众多研究,但至今尚不理想。化学诱导性结肠炎是比较广泛采用的UC模型,包括葡聚糖硫酸钠(Dextran Sulfate soduium,DSS)及2,4,6-三硝基苯磺酸(Trinitrobenzene Sulfonic Acid,TNBS)诱导性结肠炎模型。DSS诱导性结肠炎主要在结肠远端,其病理表现符合UC的特点,但是这个模型的一个很大的障碍是DSS非常昂贵。TNBS诱导性结肠炎模型是一种经典的炎症性肠病模型,诱导后产生的远端结肠病变持续存在,有许多学者把TNBS诱导性结肠炎模型作为UC的模型。
为了验证云母灌肠对结肠炎的治疗作用,我们首先建立起两种动物模型并对其疗效进行双重验证。我们重复了经典的TNBS诱导性结肠炎,并尝试建立了一种新的复合型大鼠DSS/乙醇化学诱导性结肠炎模型。将雌性SD大鼠随机分为4组,A组为模型组,B组和C组为阳性对照组,D组为正常对照组。A组和B组的大鼠自由饮用2%DSS 3天,C组和D组的大鼠自由饮用消毒后的自来水3天。第4天,A组和B组的大鼠分别灌肠内注入0.5ml 30%乙醇或生理盐水,C组和D组分别结肠内灌注0.5ml 30%乙醇或生理盐水。各组进行疾病活动指数的评分,同时在结肠注入乙醇或生理盐水后24小时、3天、7天、14天和21天随机处死每组大鼠各5只进行大体评分和病理评分;结果显示模型组大鼠自由饮用2%DSS 3天后灌肠注入30%乙醇可以诱导出现类似UC的体重下降、腹泻和血便。大体可见远端结肠有溃疡和炎症,病理显示炎症细胞侵润、隐窝脓肿和异型增生等UC的的病理特点。和正常对照组相比,模型组大鼠的体重明显减少,结肠的大体和病理积分增加;该模型和人类UC具有类似的临床和形态特点,且相对价格便宜、制作简单。
我们先以云母灌肠治疗大鼠DSS/乙醇化学诱导性结肠炎来确认云母的治疗作用。正常对照组、DSS/乙醇模型组、云母治疗组、5-ASA治疗组在制模的当天开始灌肠用药,连续用药10天。观察治疗前后大鼠体重的改变和治疗后大鼠结肠的大体和病理积分。云母或5-ASA灌肠治疗DSS/乙醇结肠炎后大鼠体重减少的情况有明显改善,同时大体积分明显减少,病理积分也同样明显减少。通过该部分研究明确了云母灌肠治疗DSS/乙醇化学诱导性结肠炎有效。
然后进一步在TNBS诱导性结肠炎模型上进行量效研究。TNBS诱导性结肠炎模型建立的当天分别给予低剂量云母(240mg/kg/d)、中剂量云母(480mg/kg/d)、高剂量云母(960mg/kg/d)和5-ASA(360mg/kg/d)灌肠。用药14天后,比较大鼠治疗前后体重改变情况和结肠的大体、病理积分;结肠灌注不同剂量的云母可以剂量相关地改善TNBS诱导性结肠炎大鼠的体重减少现象,同时减少大鼠结肠的大体和病理积分。该部分研究提示云母治疗结肠炎有量效关系。
为了进一步探讨云母起效的可能机制,我们接着对云母作用的体内和体外机制进行深入的研究。过度的免疫反应是UC炎症和组织损伤的内在重要因素,而细胞因子在调节肠道免疫反应中扮演重要角色,与UC的发生及转归密切相关。与UC发病有关的细胞因子主要有TNF-a(Tumor Necrosis Factor-α,TNF-α)、IL-1β(Interleukin-1β,IL-1β)、IL-8等。我们采用大鼠TNBS诱导性结肠炎模型在体内水平深入研究了云母灌肠治疗后大鼠结肠局部TNF-α、IL-1β的基因和蛋白的改变情况。TNBS大鼠结肠炎模型制模的当天随机分组,分别给予低剂量云母、中剂量云母、高剂量云母和5-ASA灌肠。用药14天后,PT-PCR检测结肠组织中TNF-α、IL-1β、粘蛋白2(Mucin 2,MUC2)和肠三叶因子(Intestinal Trefoil Factor,ITF)的mRNA含量。ELISA方法检测结肠组织中TNF-α、IL-1β蛋白含量,免疫组化和AB-PAS(Alcian blue/periodic acid-Schiff reaction)染色检测粘蛋白分布情况。结果显示TNBS诱导性结肠炎大鼠的结肠组织中TNF-α、IL-1β的mRNA和蛋白水平均明显增加,云母和5-ASA灌肠可以减少结肠炎大鼠结肠中TNF-α、IL-1β的mRNA和蛋白量。同时还发现TNBS诱导性结肠炎大鼠结肠中MUC2 mRNA明显下降,云母和5-ASA灌肠治疗后有所上升。但是,各组结肠中ITF mRNA无明显改变。该部分研究提示云母灌肠治疗可以明显降低TNBS诱导性结肠炎局部的TNF-α、IL-1β的mRNA和蛋白水平。
最后采用THP-1和HT-29两种细胞株TNF-α、IL-1β和IL-8三种细胞因子的标准品在体外研究了云母对这三种细胞因子的作用情况。ELISA方法检测云母对脂多糖(Lipopolysaccharide,LPS)刺激后的THP-1和HT-29两种细胞株分泌的细胞因子TNF-α、IL-1β及IL-8的影响情况。ELISA方法检测不同剂量的云母和TNF-α、IL-1β及IL-8三种标准品共同孵育1小时后这三种细胞因子的变化情况。结果显示云母可以剂量依赖性地减少THP-1细胞株分泌的TNF-α、IL-1β和HT-29细胞株分泌的IL-8蛋白含量。TNF-α、IL-1β及IL-8这三种细胞因子的标准品在和云母共同孵育1小时后都有明显的剂量依赖性的下降。
通过上述实验,我们成功建立一种新的符合人类UC的大鼠化学诱导性结肠炎模型;明确了云母灌肠对两种化学诱导性结肠炎的治疗作用并摸索出量效关系。云母治疗作用机制与降低肠道局部的TNF-α、IL-1β的mRNA和蛋白有关,云母能吸附肠道各种细胞所释放的细胞因子可能是其起效的机制之一。
Ulcerative colitis(UC) is an inflammatory disease of unknown cause that exhibits a clinical course with remission and exacerbations,characterized by abdominal pain, rectal bleeding and diarrhea.Inflammation usually occurs in the rectum and lower part of the colon.The number of cases increased rapidly in China.With long term of bowel symptoms and systemic symptoms,the quality of life and social function of patients are also affected severely.The research of UC is a hot topic nowadays.
One study showed 70.2%were proctosigmoiditis or proctitis.For the treatment of UC confined to the rectum and sigmoid,topical administration of medicines,such as glucocorticoids and 5-aminosalicylic acid(5-ASA),to the injured colonic mucosa has been shown to be more effective and less hazardous than systemic administration. However,current topical treatments for UC have their limitations.For example,the high price of 5-ASA prevents it to be wildly used in our country.When applying glucocorticoids topically,there is still a significant absorption of glucocorticoids through the inflamed mucosa that causes systemic effects.It is necessary to develop alternative therapeutic approaches that are effective,affordable and have less adverse effects.
Muscovite is one kind of natural clay consisting of an insoluble double silicate of aluminium and magnesium.In traditional Chinese medicine it has been documented that muscovite has antidiarrheal activity and can protect mucosa.It's possible that rectal administration of muscovite can alleviate inflammation of UC.
Adequate animal model of UC is a useful tool of research on the therapeutic agents.Several models of experimental colitis resembling ulcerative colitis have been reported previously.The most widely used models are induced by administering toxic chemical such as dextran sulfate sodium(DSS),trinitrobenzene sulfonic acid(TNBS). However,DSS-induced colitis results in inflammation mainly in the distal colonic mucosa.The histopathology of this model showed some characteristics resemblance to UC,enabling research into the pathogenesis and therapy of this disease.But an obvious obstacle with regard to the DSS model is that DSS is very expensive.Thus it is difficulty to apply this model widely in some regions.TNBS-induced colitis is a traditional model of inflammatory bowel disease and is widely used.
In order to investigate whether rectal administration of muscovite can alleviate inflammation of UC,we established two animal models of UC to doublely check its effect.Besides TNBS-induced colitis,we developed an inexpensive DSS/ethanol model of UC rats.Female rats were randomized into four groups.In group A and B rats received 2%dextran sulfate sodium in the drinking water for 3 days.On day 4,rats in group A and B received 0.5ml 30%ethanol or saline intracolonically respectively.As a control,rats in group C and D only received intracolonic 30%ethanol or saline respectively.Before enema,the rats were lightly anesthetized with ether.30%ethanol or saline was instilled into the lumen of the colon through the rubber catheter.Disease Activity Index(DAI) was used to quantify the clinical evolution of every group.At various times(24h,3 th day,7th day,14 th day and 21 th day) after intracolonic administration of 30%ethanol or control saline,5 rats from each treatment group were randomly selected and killed to assess for colonic inflammatory and ulcerative responses with respect to gross morphologic damage and histopathologic scoring system.The results showed the DSS/ethanol induced significant weight loss,diarrhea and hematochezia in rats.Ulcerations and inflammation of the distal part of rat colon were developed rapidly.Histological examination showed an increased infiltration of polymorphonuclear leukocytes,lymphocytes and existence of cryptic abscesses and dysplasia.The weight of rat with colitis was decreased while the gross morphologic and histopathologic scores were increased.The successfully established DSS/ethanol model is characterized by a clinical course,localization of the lesions and histopathological features similar to human UC while it is much cheaper than DSS model.
First we examined the effect of rectal administration of muscovite on DSS/ethanol induced colitis.The experimental animals were randomly divided into 4 groups to take the rectal administration of muscovite,5-ASA and the equal amount of control respectively from beginning of the induction of the colitis rats to the end of study while another group was administrated rectally with only saline served as normal control. After 10 days of treatment,the animals were assessed for colonic inflammatory and ulcerative responses with respect to change of body weight,gross morphologic damage and histopathologic scoring system.The results showed the loss of weight in the colitis groups was significantly higher than that of normal group(P＜0.01).Rectal administration of muscovite improved the loss of body weight of DSS/ethanol induced colitis.Treatment of rats with muscovite or 5-ASA decreased both morphologic and histopathologic scores of DSS/ethanol induced rats.This part showed that rectal administration of muscovite could ameliorate colonic inflammation of DSS/ethanol induced colitis.
Then we examined the effect of administration of different dosage of muscovite on TNBS-induced colitis in rats.Female SD rats with TNBS-induced colitis were treated with rectal administration of different dosage of muscovite daily for 14 days.The changes in body weight,macroscopic damage and histologic scores were subsequently evaluated.The effect of muscovite was compared with that of 5-ASA.We found rectal administration of muscovite improved the loss of body weight,macroscopic and histologic scores of TNBS-induced colitis in a dose-dependent manner.This part showed that rectal administration of different dosage of muscovite could ameliorate colonic inflammation of TNBS-induced colitis.
Based on these observations we proved that muscovite is useful for the treatment of these two kinds of colitis.Further experiments were also done to ascertain the possible mechanisms involved in the anti-inflammtory effect of muscovite.An exaggerated intestinal immune response in colon plays a key role in the pathophysiology of UC.Pathological processes accompanying UC are associated with aberrant expression of many proinflammatory cytokines,including tumor necrosis factor-α(TNF-α),Interleukin-1β(IL-1β) and IL-8.To ascertain the possible mechanisms involoed in the anti-inflammtory effect of muscovite,we examined the effect of muscovite on the mucosal inflammatory changes by studying the expression of IL-1βand TNF-αin the colonic tissues in rats with TNBS-induced colitis.Female SD rats with TNBS-induced colitis were treated with rectal administration of different dosage of muscovite daily for 14 days.Gene expression of TNF-α,IL-1β,mucin2 (MUC2) and intestinal trefoil factor(ITF) in the colonic tissues was assessed by semiquantitative reverse-transcription polymerase chain reaction(RT-PCR) while protein levels of TNF-αand IL-1βwere detected by enzyme-linked immunosorbent assay(ELISA).MUC2 expression in colonic mucosa was detected by immunohistochemistry and Alcian blue-periodic acid Schiff(AB-PAS).The results showed TNBS-induced expression of TNF-α,IL-1βwas reduced by administration of muscovite and 5-ASA.Reduction of MUC2 expression in colitis rats was reversed by muscovite and 5-ASA treatment.However,the expression of ITF mRNA in colonic mucosa was not affected.This part showed rectal administration of different dosage of muscovite can decrease the expression of TNF-α,IL-1β.
In the end,the capacity of muscovite to adsorb cytokines in vitro was determine by measuring the residual amount of standard TNF-α,IL-1βand IL-8 after these cytokines were incubated with muscovite for 1 hours as well as the changes in the amount of TNF-α,IL-1βsecreted by lipopolysaccharide(LPS)-stimulated THP-1 cells and IL-8 secreted by LPS- stimulated HT-29 cells.Muscovite inhibited the expression of TNF-α, IL-1βsecreted by THP-1 and IL-8 secreted by HT-29 cells in a dose-dependent manner. The levels of standard TNF-α,IL-1βand IL-8 were also decreased dramatically after incubating with muscovite for 1 hour.
In conclusion,we successfully established a model of chemincal-induced experimental colitis which is characterized by a clinical course,localization of the lesions and histopathological features similar to human UC.We confirmed that rectal administration of muscovite can ameliorate colonic inflammation of two different kinds of chemical-induced experimental colitis and can ameliorate colonic inflammation of TNBS-induced colitis in dose-depend manner.The mechanism of therapeutic effect of muscovite is related with the fact that rectal administration of different dosage of muscovite can decrease the mRNA and protein expression of TNF-α,IL-1β.The possible mechanisms of muscovite include a direct adsorptive action of cytokines production by mucosal cells.
引文
[1] Wilks S.S.Morbid appearance of the intestine of miss bank.Medical Times and Gazette,1859,2:264.
[2] Kornbluth A,Sachar DB.Ulcerative colitis practice guidelines in adults.American College of Gastroenterology,Practice Parameters Committee.Am J Gastroenterol 1997;92:204-11.
[3] Kethu SR.Extraintestinal manifestations of inflammatory bowel diseases.J Clin Gastroenterol 2006;40:467-75.
[4] Orchard TR,Chua CN,Ahmad T,Cheng H,Welsh KI,Jewell DP.Uveitis and erythema nodosum in inflammatory bowel disease:clinical features and the role of HLA genes.Gastroenterology 2002;123:714-8.
[5] Christodoulou DK,Katsanos KH,Kitsanou M,Stergiopoulou C,Hatzis J,Tsianos EV.Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature.Dig Liver Dis 2002;34:781-6.
[6] Ytting H,Vind I,Bang D,Munkholm P.Sweet's syndrome~an extraintestinal manifestation in inflammatory bowel disease.Digestion 2005;72:195-200.
[7] Loftus EV,Jr.Clinical epidemiology of inflammatory bowel disease:Incidence,prevalence,and environmental influences.Gastroenterology 2004;126:1504-17.
[8] Shivananda S,Lennard-Jones J,Logan R,Fear N,Price A,Carpenter L,van Blankenstein M.Incidence of inflammatory bowel disease across Europe:is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease(EC-IBD).Gut 1996;39:690-7.
[9] Card T,Hubbard R,Logan RF.Mortality in inflammatory bowel disease:a population-based cohort study.Gastroenterology 2003;125:1583-90.
[10]邓长生,夏冰.炎症性肠病.人民卫生出版社,第二版,2006,547.
[11]Jess T,Loftus EV,Jr.,Harmsen WS,Zinsmeister AR,Tremaine WJ,Melton LJ,3rd,Munkholm P,Sandborn WJ.Survival and cause specific mortality in patients with inflammatory bowel disease:a long term outcome study in Olmsted County,Minnesota,1940-2004.Gut 2006;55:1248-54.
[12]Ouyang Q,Tandon R,Goh KL,Ooi CJ,Ogata H,Fiocchi C.The emergence of inflammatory bowel disease in the Asian Pacific region.Curr Opin Gastroenterol 2005;21:408-13.
[13]Jiang XL,Cui HF.An analysis of 10218 ulcerative colitis cases in China.World J Gastroenterol 2002;8:158-61.
[14]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见.胃肠病学2007;12:488-49.
[15]邓长生,夏冰柱主编.炎症性肠病.人民卫生出版社,第二版,2006,412.
[16]Ren WH,Lai M,Chen Y,Irvine EJ,Zhou YX.Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire(IBDQ) for ulcerative colitis and Crohn's disease.Inflamm Bowel Dis 2007;13:903-10.
[17]Eaden JA,Abrams KR,Mayberry JF.The risk of colorectal cancer in ulcerative colitis:a meta-analysis.Gut 2001;48:526-35.
[18]Bernstein CN,Blanchard JF,Kliewer E,Wajda A.Cancer risk in patients with inflammatory bowel disease:a population-based study.Cancer 2001;91:854-62.
[19]Hanauer SB.Inflammatory bowel disease.N Engl J Med 1996;334:841-8.
[20]Schreiber S,Keshavarzian A,Isaacs KL,Schollenberger J,Guzman JP,Orlandi C,Hanauer SB.A randomized,placebo-controlled,phase Ⅱ study of tetomilast in active ulcerative colitis.Gastroenterology 2007;132:76-86.
[21]Andres PG,Friedman LS.Epidemiology and the natural course of inflammatory bowel disease.Gastroenterol Clin North Am 1999;28:255-81,ⅶ.
[22]Siegel SA,Shealy DJ,Nakada MT,Le J,Woulfe DS,Probert L,Kollias G,Ghrayeb J,Vilcek J,Daddona PE.The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.Cytokine 1995;7:15-25.
[23]Baert FJ,Rutgeerts PJ.Medical therapies for ulcerative colitis and Crohn's disease.Curr Gastroenterol Rep 2000;2:446-50.
[24]Carter MJ,Lobo AJ,Travis SP.Guidelines for the management of inflammatory bowel disease in adults.Gut 2004;53 Suppl 5:V1-16.
[25]Daperno M,Sostegni R,Scaglione N,Ercole E,Rigazio C,Rocca R,Pera A.Outcome of a conservative approach in severe ulcerative colitis.Dig Liver Dis 2004;36:21-8.
[26]Hurlstone DP,McAlindon ME,Sanders DS,Koegh R,Lobo AJ,Cross SS.Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.Gastroenterology 2004;126:376-8.
[27]van Staa TP,Cooper C,Brusse LS,Leufkens H,Javaid MK,Arden NK.Inflammatory bowel disease and the risk of fracture.Gastroenterology 2003;125:1591-7.
[28]Regueiro M,Loftus EV,Jr.,Steinhart AH,Cohen RD.Medical management of left-sided ulcerative colitis and ulcerative proctitis:critical evaluation of therapeutic trials.Inflamm Bowel Dis 2006;12:979-94.
[29]McIntyre PB,Macrae FA,Berghouse L,English J,Lennard-Jones JE.Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis.Gut 1985;26:822-4.
[30]Kuhbacher T,Folsch UR.Practical guidelines for the treatment of inflammatory bowel disease.World J Gastroenterol 2007;13:1149-55.
[31]宋立人,洪恂,丁诸亮主编.现代中药学大词典.人民卫生出版社,第二 版,2005,111.
[32]Zhu FS,Si JM,Wang LJ,Wang DF,Chen P.Effect of mica granule on the expression of gene-protein associated with cancer in gastric mucosa tissue of chronic atrophic gastritis rats.Zhongguo Zhong Yao Za Zhi 2006;31:312-6.
[33]Zhu FS,Wang LJ,Si JM,Wang DF,Chen P.Effect of mica monomer granule on gastrin,somatostatin and G cells as well as D cells of gastric mucosa in CAG rat.Zhongguo Zhong Yao Za Zhi 2004;29:554-8.
[34]姒健敏,钱云,吴加国.云母对实验性胃溃疡愈合质量的影响.中国中药杂志2005;30:1536-41.
[35]朱曙东,李彬裴,乔樵.云母粉对脾虚泄泻大鼠淀粉酶、木糖的影响.浙江中医学院学报 2002,12:46-47.
[36]Osman N,Adawi D,Ahrne S,Jeppsson B,Molin G.Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium.Dig Dis Sci 2004;49:320-7.
[37]Gaudio E,Taddei G,Vetuschi A,Sferra R,Frieri G,Ricciardi G,Caprilli R.Dextran sulfate sodium(DSS) colitis in rats:clinical,structural,and ultrastructural aspects.Dig Dis Sci 1999;44:1458-75.
[38]Ekstrom GM.Oxazolone-induced colitis in rats:effects of budesonide,cyclosporin A,and 5-aminosalicylic acid.Scand J Gastroenterol 1998;33:174-9.
[39]Morris GP,Beck PL,Herridge MS,Depew WT,Szewczuk MR,Wallace JL.Hapten-induced model of chronic inflammation and ulceration in the rat colon.Gastroenterology 1989;96:795-803.
[40]Cooper HS,Murthy SN,Shah RS,Sedergran DJ.Clinicopathologic study of dextran sulfate sodium experimental murine colitis.Lab Invest 1993;69:238-49.
[41]Faure M,Moennoz D,Montigon F,Mettraux C,Mercier S,Schiffrin EJ,Obled C,Breuille D,Boza J.Mucin production and composition is altered in dextran sulfate sodium-induced colitis in rats.Dig Dis Sci 2003;48:1366-73.
[42] Ni J,Chen SF,Hollander D.Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes.Gut 1996;39:234-41.
[43] Okayasu I,Hatakeyama S,Yamada M,Ohkusa T,Inagaki Y,Nakaya R.A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.Gastroenterology 1990;98:694-702.
[44] Vicario M,Crespi M,Franch A,Amat C,Pelegri C,Moreto M.Induction of colitis in young rats by dextran sulfate sodium.Dig Dis Sci 2005;50:143-50.
[45] Ohtsuka Y,Sanderson IR.Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice.Pediatr Res 2003;53:143-7.
[46] Egger B,Bajaj-Elliott M,MacDonald TT,Inglin R,Eysselein VE,Buchler MW.Characterisation of acute murine dextran sodium sulphate colitis:cytokine profile and dose dependency.Digestion 2000;62:240-8.
[47] Bamias G,Nyce MR,De La Rue SA,Cominelli F.New concepts in the pathophysiology of inflammatory bowel disease.Ann Intern Med 2005;143:895-904.
[48] Ward M.The pathogenesis of Crohn's disease.Lancet 1977;2:903-5.
[49] Shorter RG,Huizenga KA,Spencer RJ.A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease.Am J Dig Dis 1972;17:1024-32.
[50] Tsune I,Ikejima K,Hirose M,Yoshikawa M,Enomoto N,Takei Y,Sato N.Dietary glycine prevents chemical-induced experimental colitis in the rat.Gastroenterology 2003;125:775-85.
[51] Dohi T,Fujihashi K,Rennert PD,Iwatani K,Kiyono H,McGhee JR.Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses.J Exp Med 1999;189:1169-80.
[52]Matsuura M,Okazaki K,Nishio A,Nakase H,Tamaki H,Uchida K,Nishi T,Asada M,Kawasaki K,Fukui T,Yoshizawa H,Ohashi S,Inoue S,Kawanami C,Hiai H,Tabata Y,Chiba T.Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.Gastroenterology 2005;128:975-86.
[53]Gonzalez R,de Medina FS,Martinez-Augustin O,Nieto A,Galvez J,Risco S,Zarzuelo A.Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat.Br J Pharmacol 2004;141:951-60.
[54]孙士然,陈雪清.加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例.时珍国医国药 2006;17:1537-8.
[55]张瑞霞.中西医结合灌肠治疗慢性溃疡性结肠炎32例.江苏中医药2003;24:29.
[56]刘雪梅,甘德春.疡愈汤保留灌肠治疗溃疡性结肠炎56例.华西医学2006;21:576-7.
[57]宋 李昉等 编纂.太平御览 一千卷2002,10月第一版 中国历代基本典籍库 中国北京国学时代文化传播有限公司研制.
[58]Isozaki Y,Yoshida N,Kuroda M,Handa O,Takagi T,Kokura S,Ichikawa H,Naito Y,Okanoue T,Yoshikawa T.Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis.Scand J Gastroenterol 2006;41:944-53.
[59]Siddiqui A,Ancha H,Tedesco D,Lightfoot S,Stewart CA,Harty RF.Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis.Dig Dis Sci 2006;51:698-705.
[60]Marshall JK,Irvine EJ.Putting rectal 5-aminosalicylic acid in its place:the role in distal ulcerative colitis.Am J Gastroenterol 2000;95:1628-36.
[61]Corrigan G,Stevens PE.Review article:interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.Aliment Pharmacol Ther 2000;14:1-6.
[62] Rosa N,Giamundo A,Jura A,Iaccarino G,Romano A.Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis.Am J Ophthalmol 2003;136:212-3.
[63] Fiocchi C. Inflammatory bowel disease:etiology and pathogenesis.Gastroenterology 1998;115:182-205.
[64] MacDonald TT.Effector and regulatory lymphoid cells and cytokines in mucosal sites.Curr Top Microbiol Immunol 1999;236:113-35.
[65] Strober W,Ludviksson BR,Fuss IJ.The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease.Ann Intern Med 1998;128:848-56.
[66] Elson CO,Cong Y,Brandwein S,Weaver CT,McCabe RP,Mahler M,Sundberg JP,Leiter EH.Experimental models to study molecular mechanisms underlying intestinal inflammation.Ann N Y Acad Sci 1998;859:85-95.
[67] Bhan AK,Mizoguchi E,Smith RN,Mizoguchi A.Lessons for human inflammatory bowel disease from experimental models. Curr Opin Gastroenterol 1999;15:285.
[68] O'Garra A.Cytokines induce the development of functionally heterogeneous T helper cell subsets.Immunity 1998;8:275-83.
[69] Kam LY,Targan SR.Cytokine-based therapies in inflammatory bowel disease.Curr Opin Gastroenterol 1999;15:302.
[70] Radema SA,van Deventer SJ,Cerami A.Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis.Gastroenterology 1991;100:1180-6.
[71] Katsuta T,Lim C,Shimoda K,Shibuta K,Mitra P,Banner BF,Mori M,Barnard GF.Interleukin-8 and SDF1-alpha mRNA expression in colonic biopsies from patients with inflammatory bowel disease.Am J Gastroenterol 2000;95:3157-64.
[72] Guimbaud R,Bertrand V,Chauvelot-Moachon L,Quartier G,Vidon N,Giroud JP,Couturier D,Chaussade S.Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.Am J Gastroenterol 1998;93:2397-404.
[73] Nielsen OH,Gionchetti P,Ainsworth M,Vainer B,Campieri M,Borregaard N,Kjeldsen L.Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin,interleukin-8,and tumor necrosis factor-alpha in ulcerative colitis.Am J Gastroenterol 1999;94:2923-8.
[74] Harada K,Toyonaga A,Mitsuyama K,Sasaki E,Tanikawa K.Role of cytokine-induced neutrophil chemoattractant,a member of the interleukin-8 family,in rat experimental colitis.Digestion 1994;55:179-84.
[75] Mackay F,Browning JL,Lawton P,Shah SA,Comiskey M,Bhan AK,Mizoguchi E,Terhorst C,Simpson SJ.Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis.Gastroenterology 1998;115:1464-75.
[76] Elson CO,Sartor RB,Tennyson GS,Riddell RH.Experimental models of inflammatory bowel disease.Gastroenterology 1995;109:1344-67.
[77] Bobin-Dubigeon C,Collin X,Grimaud N,Robert JM,Le Baut G,Petit JY.Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis.Eur J Pharmacol 2001;431:103-10.
[78] Van Klinken BJ,Dekker J,Buller HA,Einerhand AW.Mucin gene structure and expression:protection vs.adhesion.Am J Physiol 1995;269:G613-27.
[79] Gendler SJ,Spicer AP.Epithelial mucin genes.Annu Rev Physiol 1995;57:607-34.
[80] Tytgat KM,Buller HA,Opdam FJ,Kim YS,Einerhand AW,Dekker J.Biosynthesis of human colonic mucin:Muc2 is the prominent secretory mucin.Gastroenterology 1994;107:1352-63.
[81] McCormick DA,Horton LW,Mee AS.Mucin depletion in inflammatory bowel disease.J Clin Pathol 1990;43:143-6.
[82] Shaoul R,Okada Y,Cutz E,Marcon MA.Colonic expression of MUC2,MUC5AC,and TFF1 in inflammatory bowel disease in children.J Pediatr Gastroenterol Nutr 2004;38:488-93.
[83] Loncar MB,Al-azzeh ED,Sommer PS,Marinovic M,Schmehl K,Kruschewski M,Blin N,Stohwasser R,Gott P,Kayademir T.Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide.Gut 2003;52:1297-303.
[84] Enss ML,Cornberg M,Wagner S,Gebert A,Henrichs M,Eisenblatter R,Beil W,Kownatzki R,Hedrich HJ.Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180.Inflamm Res 2000;49:162-9.
[85] Lin J,Nadroo AM,Chen W,Holzman IR,Fan QX,Babyatsky MW.Ontogeny and prenatal expression of trefoil factor 3/ITF in the human intestine.Early Hum Dev 2003;71:103-9.
[86] Yu K,Jiang SF,Lin MF,Wu JB,Lin J.Extraction and purification of biologically active intestinal trefoil factor from human meconium.Lab Invest 2004;84:390-2.
[87] Blanchard C,Durual S,Estienne M,Bouzakri K,Heim MH,Blin N,Cuber JC.IL-4 and IL-13 up-regulate intestinal trefoil factor expression:requirement for STAT6 and de novo protein synthesis.J Immunol 2004;172:3775-83.
[88] Dignass A,Lynch-Devaney K,Kindon H,Thim L,Podolsky DK.Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway.J Clin Invest 1994;94:376-83.
[89] Kinoshita K,Taupin DR,Itoh H,Podolsky DK.Distinct pathways of cell migration and antiapoptotic response to epithelial injury:structure-function analysis of human intestinal trefoil factor.Mol Cell Biol 2000;20:4680-90.
[90] Podolsky DK.Mechanisms of regulatory peptide action in the gastrointestinal tract:trefoil peptides.J Gastroenterol 2000;35 Suppl 12:69-74.
[91] Tran CP,Cook GA,Yeomans ND,Thim L,Giraud AS.Trefoil peptide TFF2(spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis.Gut 1999;44:636-42.
[92] Itoh H,Tomita M,Uchino H,Kobayashi T,Kataoka H,Sekiya R,Nawa Y.cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis.Biochem J 1996;318(Pt 3):939-44.
[93] Tomita M,Itoh H,Ishikawa N,Higa A,Ide H,Murakumo Y,Maruyama H,Koga Y,Nawa Y.Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes.Biochem J 1995;311(Pt 1):293-7.
[94] Ogata H,Podolsky DK.Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine.Am J Physiol 1997;273:G348-54.
[95] Gardiner KR,Halliday MI,Barclay GR,Milne L,Brown D,Stephens S,Maxwell RJ,Rowlands BJ.Significance of systemic endotoxaemia in inflammatory bowel disease.Gut 1995;36:897-901.
[96] Jung HC,Eckmann L,Yang SK,Panja A,Fierer J,Morzycka-Wroblewska E,Kagnoff MF.A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.J Clin Invest 1995;95:55-65.
[97] Gibson P,Rosella O.Interleukin 8 secretion by colonic crypt cells in vitro:response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.Gut 1995;37:536-43.
[98] Geppert TD,Whitehurst CE,Thompson P,Beutler B.Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway.Mol Med 1994;1:93-103.
[99] Su C,Salzberg BA,Lewis JD,Deren JJ,Kornbluth A,Katzka DA,Stein RB,Adler DR,Lichtenstein GR.Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.Am J Gastroenterol 2002;97:2577-84.
[100] Komatsu M,Kobayashi D,Saito K,Furuya D,Yagihashi A,Araake H,Tsuji N,Sakamaki S,Niitsu Y,Watanabe N.Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR.Clin Chem 2001;47:1297-301.
[101] Masuda H,Iwai S,Tanaka T,Hayakawa S.Expression of IL-8,TNF-alpha and IFN-gamma m-RNA in ulcerative colitis,particularly in patients with inactive phase.J Clin Lab Immunol 1995;46:111-23.
[102] Akazawa A,Sakaida I,Higaki S,Kubo Y,Uchida K,Okita K.Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,particularly in patients with disease in the inactive phase.J Gastroenterol 2002;37:345-53.
[103] Stevens C,Walz G,Singaram C,Lipman ML,Zanker B,Muggia A,Antonioli D,Peppercorn MA,Strom TB.Tumor necrosis factor-alpha,interleukin-1 beta,and interleukin-6 expression in inflammatory bowel disease.Dig Dis Sci 1992;37:818-26.
[104] Sawa Y,Oshitani N,Adachi K,Higuchi K,Matsumoto T,Arakawa T.Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.Int J Mol Med 2003;11:175-9.
[105] Gisbert JP,Gonzalez-Lama Y,Mate J.Systematic review:Infliximab therapy in ulcerative colitis.Aliment Pharmacol Ther 2007;25:19-37.
[106] Lawson MM,Thomas AG,Akobeng AK.Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.Cochrane Database Syst Rev 2006;3:CD005112.
[107] Rutgeerts P,Sandborn WJ,Feagan BG,Reinisch W,Olson A,Johanns J,Travers S,Rachmilewitz D,Hanauer SB,Lichtenstein GR,de Villiers WJ,Present D,Sands BE,Colombel JF.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med 2005;353:2462-76.
[108] McAlindon ME,Hawkey CJ,Mahida YR.Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease.Gut 1998;42:214-9.
[109] Mahida YR,Wu K,Jewell DP.Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.Gut 1989;30:835-8.
[110] Ligumsky M,Simon PL,Karmeli F,Rachmilewitz D.Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.Gut 1990;31:686-9.
[111] Saiki T,Mitsuyama K,Toyonaga A,Ishida H,Tanikawa K.Detection of pro-and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease.Scand J Gastroenterol 1998;33:616-22.
[112] Daig R,Andus T,Aschenbrenner E,Falk W,Scholmerich J,Gross V.Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.Gut 1996;38:216-22.
[113] Ina K,Kusugami K,Yamaguchi T,Imada A,Hosokawa T,Ohsuga M,Shinoda M,Ando T,Ito K,Yokoyama Y.Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease.Am J Gastroenterol 1997;92:1342-6.
[114] Keshavarzian A,Fusunyan RD,Jacyno M,Winship D,MacDermott RP, Sanderson IR.Increased interleukin-8(IL-8)in rectal dialysate from patients with ulcerative colitis:evidence for a biological role for IL-8 in inflammation of the colon.Am J Gastroenterol 1999;94:704-12.
[115] Descoteaux A,Matlashewski G.Regulation of tumor necrosis factor gene expression and protein synthesis in murine macrophages treated with recombinant tumor necrosis factor.J Immunol 1990;145:846-53.
[116] Nawroth PP,Bank I,Handley D,Cassimeris J,Chess L,Stern D.Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.J Exp Med 1986;163:1363-75.
[117] Casellas F,Papo M,Guarner F,Antolin M,Armengol JR,Malagelada JR.Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.Clin Sci(Lond)1994;87:453-8.
[118] Sangfelt P,Carlson M,Thorn M,Xu S,Loof L,Raab Y.Local release of human neutrophil lipocalin(HNL),IL-8,and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis.Dig Dis Sci 2002;47:2064-9.
[119] Dinarello CA.Interleukin-1 and its biologically related cytokines.Adv Immunol 1989;44:153-205.
[120] Di Giovine FS,Duff GW.Interleukin 1:the first interleukin.Immunol Today 1990;11:13-20.
[121] Aggarwal BB,Natarajan K.Tumor necrosis factors:developments during the last decade.Eur Cytokine Netw 1996;7:93-124.
[122] Van Hogezand RA,Verspaget HW.Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality? Neth J Med 1996;48:64-7.
[1]Van Klinken BJ,Dekker J,Buller HA,Einerhand AW.Mucin gene structure and expression:protection vs.adhesion.Am J Physiol 1995;269:G613-27.
[2]Gendler SJ,Spicer AP.Epithelial mucin genes.Annu Rev Physiol 1995;57:607-34.
[3]Kim YS,Gum J,Jr.,Brockhausen I.Mucin glycoproteins in neoplasia.Glycoconj J 1996;13:693-707.
[4] Leikauf GD,Borchers MT,Prows DR,Simpson LG.Mucin apoprotein expression in COPD.Chest 2002;121:166S-182S.
[5] Tytgat KM,Bovelander FJ,Opdam FJ,Einerhand AW,Buller HA,Dekker J.Biosynthesis of rat MUC2 in colon and its analogy with human MUC2.Biochem J 1995;309(Pt 1):221-9.
[6] Tytgat KM,Buller HA,Opdam FJ,Kim YS,Einerhand AW,Dekker J.Biosynthesis of human colonic mucin:Muc2 is the prominent secretory mucin.Gastroenterology 1994;107:13 52-63.
[7] Williams SJ,McGuckin MA,Gotley DC,Eyre HJ,Sutherland GR,Antalis TM.Two novel mucin genes down-regulated in colorectal cancer identified by differential display.Cancer Res 1999;59:4083-9.
[8] Allen A,Hutton DA,Pearson JP.The MUC2 gene product:a human intestinal mucin.Int J Biochem Cell Biol 1998;30:797-801.
[9] Gum JR,Jr.,Hicks JW,Toribara NW,Rothe EM,Lagace RE,Kim YS.The human MUC2 intestinal mucin has cysteine-rich subdomains located both upstream and downstream of its central repetitive region.J Biol Chem 1992;267:21375-83.
[10] Gum JR,Jr.,Hicks JW,Toribara NW,Siddiki B,Kim YS.Molecular cloning of human intestinal mucin(MUC2)cDNA.Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor.J Biol Chem 1994;269:2440-6.
[11] Xu G,Huan LJ,Khatri IA,Wang D,Bennick A,Fahim RE,Forstner GG,Forstner JF.cDNA for the carboxyl-terminal region of a rat intestinal mucin-like peptide.J Biol Chem 1992;267:5401-7.
[12] Hansson GC,Baeckstrom D,Carlstedt I,Klinga-Levan K.Molecular cloning of a cDNA coding for a region of an apoprotein from the 'insoluble' mucin complex of rat small intestine. Biochem Biophys Res Commun 1994;198:181-90.
[13] Dekker J,Strous GJ.Covalent oligomerization of rat gastric mucin occurs in the rough endoplasmic reticulum,is N-glycosylation-dependent,and precedes initial O-glycosylation.J Biol Chem 1990;265:18116-22.
[14] Renes IB,Boshuizen JA,Van Nispen DJ,Bulsing NP,Buller HA,Dekker J,Einerhand AW.Alterations in Muc2 biosynthesis and secretion during dextran sulfate sodium-induced colitis.Am J Physiol Gastrointest Liver Physiol 2002;282:G382-9.
[15] Nieuw Amerongen AV,Bolscher JG,Bloemena E,Veerman EC.Sulfomucins in the human body.Biol Chem 1998;379:1-18.
[16] Julian J,Carson DD.Formation of MUCl metabolic complex is conserved in tumor-derived and normal epithelial cells.Biochem Biophys Res Commun 2002;293:1183-90.
[17] Velcich A,Yang W,Heyer J,Fragale A,Nicholas C,Viani S,Kucherlapati R,Lipkin M,Yang K,Augenlicht L.Colorectal cancer in mice genetically deficient in the mucin Muc2.Science 2002;295:1726-9.
[18] Jass JR,Roberton AM.Colorectal mucin histochemistry in health and disease:a critical review.Pathol Int 1994;44:487-504.
[19] van Klinken BJ,Einerhand AW,Duits LA,Makkink MK,Tytgat KM,Renes IB,Verburg M,Buller HA,Dekker J.Gastrointestinal expression and partial cDNA cloning of murine Muc2.Am J Physiol 1999;276:G115-24.
[20] Tytgat KM,Buller HA,Einerhand AW,van Deventer SJ,Dekker J.[Role of mucins in inflammatory intestinal diseases],Ned Tijdschr Geneeskd 1994;138:2386-90.
[21] McCormick DA,Horton LW,Mee AS.Mucin depletion in inflammatory bowel disease.J Clin Pathol 1990;43:143-6.
[22] Shaoul R,Okada Y,Cutz E,Marcon MA.Colonic expression of MUC2,MUC5AC,and TFF1 in inflammatory bowel disease in children.J Pediatr Gastroenterol Nutr 2004;38:488-93.
[23] Renes IB,Verburg M,Van Nispen DJ,Taminiau JA,Buller HA,Dekker J,Einerhand AW.Epithelial proliferation,cell death,and gene expression in experimental colitis:alterations in carbonic anhydrase I,mucin MUC2,and trefoil factor 3 expression.Int J Colorectal Dis 2002;17:317-26.
[24] Hanski C,Born M,Foss HD,Marowski B,Mansmann U,Arasteh K,Bachler B,Papenfuss M,Niedobitek F.Defective post-transcriptional processing of MUC2 mucin in ulcerative colitis and in Crohn's disease increases detectability of the MUC2 protein core.J Pathol 1999;188:304-11.
[25] Van Klinken BJ,Van der Wal JW,Einerhand AW,Buller HA,Dekker J.Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis.Gut 1999;44:387-93.
[26] Jacobs LR,Huber PW.Regional distribution and alterations of lectin binding to colorectal mucin in mucosal biopsies from controls and subjects with inflammatory bowel diseases.J Clin Invest 1985;75:112-8.
[27] Pullan RD,Thomas GA,Rhodes M,Newcombe RG,Williams GT,Allen A,Rhodes J.Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.Gut 1994;35:353-9.
[28] Theodossi A,Spiegelhalter DJ,Jass J,Firth J,Dixon M,Leader M,Levison DA,Lindley R,Filipe I,Price A,et al.Observer variation and discriminatory value of biopsy features in inflammatory bowel disease.Gut 1994;35:961-8.
[29] Tytgat KM,van der Wal JW,Einerhand AW,Buller HA,Dekker J.Quantitative analysis of MUC2 synthesis in ulcerative colitis.Biochem Biophys Res Commun 1996;224:397-405.
[30] Morita H,Kettlewell MG,Jewell DP,Kent PW.Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects.Gut 1993;34:926-32.
[31] Clamp JR,Fraser G,Read AE.Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. Clin Sci (Lond)1981;61:229-34.
[32] Feizi T,Gooi HC,Childs RA,Picard JK,Uemura K,Loomes LM,Thorpe SJ,Hounsell EF.Tumour-associated and differentiation antigens on the carbohydrate moieties of mucin-type glycoproteins.Biochem Soc Trans 1984;12:591-6.
[33] Parker N,Tsai HH,Ryder SD,Raouf AH,Rhodes JM.Increased rate of sialylation of colonic mucin by cultured ulcerative colitis mucosal explants.Digestion 1995;56:52-6.
[34] Raouf AH,Tsai HH,Parker N,Hoffman J,Walker RJ,Rhodes JM.Sulphation of colonic and rectal mucin in inflammatory bowel disease:reduced sulphation of rectal mucus in ulcerative colitis.Clin Sci(Lond)1992;83:623-6.
[35] Roediger WE,Moore J,Babidge W.Colonic sulfide in pathogenesis and treatment of ulcerative colitis.Dig Dis Sci 1997;42:1571-9.
[36] Corfield AP,Myerscough N,Bradfield N,Corfield Cdo A,Gough M,Clamp JR,Durdey P,Warren BF,Bartolo DC,King KR,Williams JM.Colonic mucins in ulcerative colitis:evidence for loss of sulfation.Glycoconj J 1996;13:809-22.
[37] Weiss AA,Babyatsky MW,Ogata S,Chen A,Itzkowitz SH.Expression of MUC2 and MUC3 mRNA in human normal,malignant,and inflammatory intestinal tissues.J Histochem Cytochem 1996;44:1161-6.
[38] Ni J,Chen SF,Hollander D.Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes.Gut 1996;39:234-41.
[39]Faure M,Moennoz D,Montigon F,Mettraux C,Mercier S,Schiffiin EJ,Obled C,Breuille D,Boza J.Mucin production and composition is altered in dextran sulfate sodium-induced colitis in rats.Dig Dis Sci 2003;48:1366-73.
[40]Thim L.A new family of growth factor-like peptides.'Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide(pS2),pancreatic spasmolytic polypeptide(PSP),and frog skin peptides(spasmolysins).FEBS Lett 1989;250:85-90.
[41]Suemori S,Lynch-Devaney K,Podolsky DK.Identification and characterization of rat intestinal trefoil factor:tissue-and cell-specific member of the trefoil protein family.Proc Natl Acad Sci U S A 1991;88:11017-21.
[42]Thim L.Trefoil peptides:from structure to function.Cell Mol Life Sci 1997;53:888-903.
[43]Taupin DR,Pang KC,Green SP,Giraud AS.The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut.Peptides 1995;16:1001-5.
[44]Podolsky DK,Lynch-Devaney K,Stow JL,Oates P,Murgue B,De-Beaumont M,Sands BE,Mahida YR.Identification of human intestinal trefoil factor.Goblet cell-specific expression of a peptide targeted for apical secretion.J Biol Chem 1993;268:12230.
[45]Taupin D,Pedersen J,Familari M,Cook G,Yeomans N,Giraud AS.Augmented intestinal trefoil factor(TFF3)and loss of pS2(TFF1)expression precedes metaplastic differentiation of gastric epithelium.Lab Invest 2001;81:397-408.
[46] Wong WM,Poulsom R,Wright NA.Trefoil peptides.Gut 1999;44:890-5.
[47]Poulsom R,Hanby AM,Lalani EN,Hauser F,Hoffmann W,Stamp GW.Intestinal trefoil factor(TFF 3)and pS2(TFF 1),but not spasmolytic polypeptide(TFF 2)mRNAs are co-expressed in normal,hyperplastic,and neoplastic human breast epithelium.J Pathol 1997;183:30-8.
[48] dos Santos Silva E,Ulrich M,Doring G,Botzenhart K,Gott P.Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000;190:133-42.
[49] Kindon H,Pothoulakis C,Thim L,Lynch-Devaney K,Podolsky DK.Trefoil peptide protection of intestinal epithelial barrier function:cooperative interaction with mucin glycoprotein.Gastroenterology 1995;109:516-23.
[50] Wright NA,Pike C,Elia G Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells.Nature 1990;343:82-5.
[51] Alison MR,Chinery R,Poulsom R,Ashwood P,Longcroft JM,Wright NA.Experimental ulceration leads to sequential expression of spasmolytic polypeptide,intestinal trefoil factor,epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach.J Pathol 1995;175:405-14.
[52] Dignass A,Lynch-Devaney K,Kindon H,Thim L,Podolsky DK.Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway.J Clin Invest 1994;94:376-83.
[53] Chinery R,Playford RJ.Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat.Clin Sci(Lond)1995;88:401-3.
[54] Babyatsky MW,deBeaumont M,Thim L,Podolsky DK.Oral trefoil peptides protect against ethanol-and indomethacin-induced gastric injury in rats.Gastroenterology 1996;110:489-97.
[55] Beck PL,Wong JF,Li Y,Swaminathan S,Xavier RJ,Devaney KL,Podolsky DK.Chemotherapy-and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor.Gastroenterology 2004;126:796-808.
[56] Efstathiou JA,Noda M,Rowan A,Dixon C,Chinery R,Jawhari A,Hattori T,Wright NA,Bodmer WF,Pignatelli M.Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells.Proc Natl Acad Sci U S A 1998;95:3122-7.
[57] Yamachika T,Werther JL,Bodian C,Babyatsky M,Tatematsu M,Yamamura Y,Chen A,Itzkowitz S.Intestinal trefoil factor:a marker of poor prognosis in gastric carcinoma.Clin Cancer Res 2002;8:1092-9.
[58] Kanai M,Mullen C,Podolsky DK.Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells.Proc Natl Acad Sci U S A 1998;95:178-82.
[59] Wright NA,Poulsom R,Stamp GW,Hall PA,Jeffery RE,Longcroft JM,Rio MC,Tomasetto C,Chambon P.Epidermal growth factor(EGF/URO)induces expression of regulatory peptides in damaged human gastrointestinal tissues.J Pathol 1990;162:279-84.
[60] Gronbaek H,Vestergaard EM,Hey H,Nielsen JN,Nexo E.Serum trefoil factors in patients with inflammatory bowel disease.Digestion 2006;74:33-9.
[61] Feng ZM,Fang DC,Chen WS,Wang RQ.Rodent IRR-219(IgGFcgammaBP)and rTFF3,Expressed Mainly in the Intestinal Mucosa,Depleted During Dextran Sulfate Sodium-Induced Colitis.Dig Dis Sci 2007.
[62] Tomita M,Itoh H,Ishikawa N,Higa A,Ide H,Murakumo Y,Maruyama H,Koga Y,Nawa Y.Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes.Biochem J 1995;311(Pt 1):293-7.
[63] Itoh H,Tomita M,Uchino H,Kobayashi T,Kataoka H,Sekiya R,Nawa Y.cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis.Biochem J I996;318(Pt 3):939-44.
[64] Mashimo H,Wu DC,Podolsky DK,Fishman MC.Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.Science 1996;274:262-5.
[65]Dossinger V,Kayademir T,Blin N,Gott P.Down-regulation of TFF expression in gastrointestinal cell lines by cytokines and nuclear factors.Cell Physiol Biochem 2002;12:197-206.
[66]Baus-Loncar M,Al-azzeh ED,Romanska H,Lalani el N,Stamp GW,Blin N,Kayademir T.Transcriptional control of TFF3(intestinal trefoil factor)via promoter binding sites for the nuclear factor kappaB and C/EBPbeta.Peptides 2004;25:849-54.
[67]Loncar MB,Al-azzeh ED,Sommer PS,Marinovic M,Schmehl K,Kruschewski M,Blin N,Stohwasser R,Gott P,Kayademir T.Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide.Gut 2003;52:1297-303.
[2] Kornbluth A,Sachar DB.Ulcerative colitis practice guidelines in adults.American College of Gastroenterology,Practice Parameters Committee.Am J Gastroenterol 1997;92:204-11.
[3] Kethu SR.Extraintestinal manifestations of inflammatory bowel diseases.J Clin Gastroenterol 2006;40:467-75.
[4] Orchard TR,Chua CN,Ahmad T,Cheng H,Welsh KI,Jewell DP.Uveitis and erythema nodosum in inflammatory bowel disease:clinical features and the role of HLA genes.Gastroenterology 2002;123:714-8.
[5] Christodoulou DK,Katsanos KH,Kitsanou M,Stergiopoulou C,Hatzis J,Tsianos EV.Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature.Dig Liver Dis 2002;34:781-6.
[6] Ytting H,Vind I,Bang D,Munkholm P.Sweet's syndrome~an extraintestinal manifestation in inflammatory bowel disease.Digestion 2005;72:195-200.
[7] Loftus EV,Jr.Clinical epidemiology of inflammatory bowel disease:Incidence,prevalence,and environmental influences.Gastroenterology 2004;126:1504-17.
[8] Shivananda S,Lennard-Jones J,Logan R,Fear N,Price A,Carpenter L,van Blankenstein M.Incidence of inflammatory bowel disease across Europe:is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease(EC-IBD).Gut 1996;39:690-7.
[9] Card T,Hubbard R,Logan RF.Mortality in inflammatory bowel disease:a population-based cohort study.Gastroenterology 2003;125:1583-90.
[10]邓长生,夏冰.炎症性肠病.人民卫生出版社,第二版,2006,547.
[11]Jess T,Loftus EV,Jr.,Harmsen WS,Zinsmeister AR,Tremaine WJ,Melton LJ,3rd,Munkholm P,Sandborn WJ.Survival and cause specific mortality in patients with inflammatory bowel disease:a long term outcome study in Olmsted County,Minnesota,1940-2004.Gut 2006;55:1248-54.
[12]Ouyang Q,Tandon R,Goh KL,Ooi CJ,Ogata H,Fiocchi C.The emergence of inflammatory bowel disease in the Asian Pacific region.Curr Opin Gastroenterol 2005;21:408-13.
[13]Jiang XL,Cui HF.An analysis of 10218 ulcerative colitis cases in China.World J Gastroenterol 2002;8:158-61.
[14]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见.胃肠病学2007;12:488-49.
[15]邓长生,夏冰柱主编.炎症性肠病.人民卫生出版社,第二版,2006,412.
[16]Ren WH,Lai M,Chen Y,Irvine EJ,Zhou YX.Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire(IBDQ) for ulcerative colitis and Crohn's disease.Inflamm Bowel Dis 2007;13:903-10.
[17]Eaden JA,Abrams KR,Mayberry JF.The risk of colorectal cancer in ulcerative colitis:a meta-analysis.Gut 2001;48:526-35.
[18]Bernstein CN,Blanchard JF,Kliewer E,Wajda A.Cancer risk in patients with inflammatory bowel disease:a population-based study.Cancer 2001;91:854-62.
[19]Hanauer SB.Inflammatory bowel disease.N Engl J Med 1996;334:841-8.
[20]Schreiber S,Keshavarzian A,Isaacs KL,Schollenberger J,Guzman JP,Orlandi C,Hanauer SB.A randomized,placebo-controlled,phase Ⅱ study of tetomilast in active ulcerative colitis.Gastroenterology 2007;132:76-86.
[21]Andres PG,Friedman LS.Epidemiology and the natural course of inflammatory bowel disease.Gastroenterol Clin North Am 1999;28:255-81,ⅶ.
[22]Siegel SA,Shealy DJ,Nakada MT,Le J,Woulfe DS,Probert L,Kollias G,Ghrayeb J,Vilcek J,Daddona PE.The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.Cytokine 1995;7:15-25.
[23]Baert FJ,Rutgeerts PJ.Medical therapies for ulcerative colitis and Crohn's disease.Curr Gastroenterol Rep 2000;2:446-50.
[24]Carter MJ,Lobo AJ,Travis SP.Guidelines for the management of inflammatory bowel disease in adults.Gut 2004;53 Suppl 5:V1-16.
[25]Daperno M,Sostegni R,Scaglione N,Ercole E,Rigazio C,Rocca R,Pera A.Outcome of a conservative approach in severe ulcerative colitis.Dig Liver Dis 2004;36:21-8.
[26]Hurlstone DP,McAlindon ME,Sanders DS,Koegh R,Lobo AJ,Cross SS.Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.Gastroenterology 2004;126:376-8.
[27]van Staa TP,Cooper C,Brusse LS,Leufkens H,Javaid MK,Arden NK.Inflammatory bowel disease and the risk of fracture.Gastroenterology 2003;125:1591-7.
[28]Regueiro M,Loftus EV,Jr.,Steinhart AH,Cohen RD.Medical management of left-sided ulcerative colitis and ulcerative proctitis:critical evaluation of therapeutic trials.Inflamm Bowel Dis 2006;12:979-94.
[29]McIntyre PB,Macrae FA,Berghouse L,English J,Lennard-Jones JE.Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis.Gut 1985;26:822-4.
[30]Kuhbacher T,Folsch UR.Practical guidelines for the treatment of inflammatory bowel disease.World J Gastroenterol 2007;13:1149-55.
[31]宋立人,洪恂,丁诸亮主编.现代中药学大词典.人民卫生出版社,第二 版,2005,111.
[32]Zhu FS,Si JM,Wang LJ,Wang DF,Chen P.Effect of mica granule on the expression of gene-protein associated with cancer in gastric mucosa tissue of chronic atrophic gastritis rats.Zhongguo Zhong Yao Za Zhi 2006;31:312-6.
[33]Zhu FS,Wang LJ,Si JM,Wang DF,Chen P.Effect of mica monomer granule on gastrin,somatostatin and G cells as well as D cells of gastric mucosa in CAG rat.Zhongguo Zhong Yao Za Zhi 2004;29:554-8.
[34]姒健敏,钱云,吴加国.云母对实验性胃溃疡愈合质量的影响.中国中药杂志2005;30:1536-41.
[35]朱曙东,李彬裴,乔樵.云母粉对脾虚泄泻大鼠淀粉酶、木糖的影响.浙江中医学院学报 2002,12:46-47.
[36]Osman N,Adawi D,Ahrne S,Jeppsson B,Molin G.Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium.Dig Dis Sci 2004;49:320-7.
[37]Gaudio E,Taddei G,Vetuschi A,Sferra R,Frieri G,Ricciardi G,Caprilli R.Dextran sulfate sodium(DSS) colitis in rats:clinical,structural,and ultrastructural aspects.Dig Dis Sci 1999;44:1458-75.
[38]Ekstrom GM.Oxazolone-induced colitis in rats:effects of budesonide,cyclosporin A,and 5-aminosalicylic acid.Scand J Gastroenterol 1998;33:174-9.
[39]Morris GP,Beck PL,Herridge MS,Depew WT,Szewczuk MR,Wallace JL.Hapten-induced model of chronic inflammation and ulceration in the rat colon.Gastroenterology 1989;96:795-803.
[40]Cooper HS,Murthy SN,Shah RS,Sedergran DJ.Clinicopathologic study of dextran sulfate sodium experimental murine colitis.Lab Invest 1993;69:238-49.
[41]Faure M,Moennoz D,Montigon F,Mettraux C,Mercier S,Schiffrin EJ,Obled C,Breuille D,Boza J.Mucin production and composition is altered in dextran sulfate sodium-induced colitis in rats.Dig Dis Sci 2003;48:1366-73.
[42] Ni J,Chen SF,Hollander D.Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes.Gut 1996;39:234-41.
[43] Okayasu I,Hatakeyama S,Yamada M,Ohkusa T,Inagaki Y,Nakaya R.A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.Gastroenterology 1990;98:694-702.
[44] Vicario M,Crespi M,Franch A,Amat C,Pelegri C,Moreto M.Induction of colitis in young rats by dextran sulfate sodium.Dig Dis Sci 2005;50:143-50.
[45] Ohtsuka Y,Sanderson IR.Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice.Pediatr Res 2003;53:143-7.
[46] Egger B,Bajaj-Elliott M,MacDonald TT,Inglin R,Eysselein VE,Buchler MW.Characterisation of acute murine dextran sodium sulphate colitis:cytokine profile and dose dependency.Digestion 2000;62:240-8.
[47] Bamias G,Nyce MR,De La Rue SA,Cominelli F.New concepts in the pathophysiology of inflammatory bowel disease.Ann Intern Med 2005;143:895-904.
[48] Ward M.The pathogenesis of Crohn's disease.Lancet 1977;2:903-5.
[49] Shorter RG,Huizenga KA,Spencer RJ.A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease.Am J Dig Dis 1972;17:1024-32.
[50] Tsune I,Ikejima K,Hirose M,Yoshikawa M,Enomoto N,Takei Y,Sato N.Dietary glycine prevents chemical-induced experimental colitis in the rat.Gastroenterology 2003;125:775-85.
[51] Dohi T,Fujihashi K,Rennert PD,Iwatani K,Kiyono H,McGhee JR.Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses.J Exp Med 1999;189:1169-80.
[52]Matsuura M,Okazaki K,Nishio A,Nakase H,Tamaki H,Uchida K,Nishi T,Asada M,Kawasaki K,Fukui T,Yoshizawa H,Ohashi S,Inoue S,Kawanami C,Hiai H,Tabata Y,Chiba T.Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.Gastroenterology 2005;128:975-86.
[53]Gonzalez R,de Medina FS,Martinez-Augustin O,Nieto A,Galvez J,Risco S,Zarzuelo A.Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat.Br J Pharmacol 2004;141:951-60.
[54]孙士然,陈雪清.加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例.时珍国医国药 2006;17:1537-8.
[55]张瑞霞.中西医结合灌肠治疗慢性溃疡性结肠炎32例.江苏中医药2003;24:29.
[56]刘雪梅,甘德春.疡愈汤保留灌肠治疗溃疡性结肠炎56例.华西医学2006;21:576-7.
[57]宋 李昉等 编纂.太平御览 一千卷2002,10月第一版 中国历代基本典籍库 中国北京国学时代文化传播有限公司研制.
[58]Isozaki Y,Yoshida N,Kuroda M,Handa O,Takagi T,Kokura S,Ichikawa H,Naito Y,Okanoue T,Yoshikawa T.Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis.Scand J Gastroenterol 2006;41:944-53.
[59]Siddiqui A,Ancha H,Tedesco D,Lightfoot S,Stewart CA,Harty RF.Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis.Dig Dis Sci 2006;51:698-705.
[60]Marshall JK,Irvine EJ.Putting rectal 5-aminosalicylic acid in its place:the role in distal ulcerative colitis.Am J Gastroenterol 2000;95:1628-36.
[61]Corrigan G,Stevens PE.Review article:interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.Aliment Pharmacol Ther 2000;14:1-6.
[62] Rosa N,Giamundo A,Jura A,Iaccarino G,Romano A.Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis.Am J Ophthalmol 2003;136:212-3.
[63] Fiocchi C. Inflammatory bowel disease:etiology and pathogenesis.Gastroenterology 1998;115:182-205.
[64] MacDonald TT.Effector and regulatory lymphoid cells and cytokines in mucosal sites.Curr Top Microbiol Immunol 1999;236:113-35.
[65] Strober W,Ludviksson BR,Fuss IJ.The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease.Ann Intern Med 1998;128:848-56.
[66] Elson CO,Cong Y,Brandwein S,Weaver CT,McCabe RP,Mahler M,Sundberg JP,Leiter EH.Experimental models to study molecular mechanisms underlying intestinal inflammation.Ann N Y Acad Sci 1998;859:85-95.
[67] Bhan AK,Mizoguchi E,Smith RN,Mizoguchi A.Lessons for human inflammatory bowel disease from experimental models. Curr Opin Gastroenterol 1999;15:285.
[68] O'Garra A.Cytokines induce the development of functionally heterogeneous T helper cell subsets.Immunity 1998;8:275-83.
[69] Kam LY,Targan SR.Cytokine-based therapies in inflammatory bowel disease.Curr Opin Gastroenterol 1999;15:302.
[70] Radema SA,van Deventer SJ,Cerami A.Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis.Gastroenterology 1991;100:1180-6.
[71] Katsuta T,Lim C,Shimoda K,Shibuta K,Mitra P,Banner BF,Mori M,Barnard GF.Interleukin-8 and SDF1-alpha mRNA expression in colonic biopsies from patients with inflammatory bowel disease.Am J Gastroenterol 2000;95:3157-64.
[72] Guimbaud R,Bertrand V,Chauvelot-Moachon L,Quartier G,Vidon N,Giroud JP,Couturier D,Chaussade S.Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.Am J Gastroenterol 1998;93:2397-404.
[73] Nielsen OH,Gionchetti P,Ainsworth M,Vainer B,Campieri M,Borregaard N,Kjeldsen L.Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin,interleukin-8,and tumor necrosis factor-alpha in ulcerative colitis.Am J Gastroenterol 1999;94:2923-8.
[74] Harada K,Toyonaga A,Mitsuyama K,Sasaki E,Tanikawa K.Role of cytokine-induced neutrophil chemoattractant,a member of the interleukin-8 family,in rat experimental colitis.Digestion 1994;55:179-84.
[75] Mackay F,Browning JL,Lawton P,Shah SA,Comiskey M,Bhan AK,Mizoguchi E,Terhorst C,Simpson SJ.Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis.Gastroenterology 1998;115:1464-75.
[76] Elson CO,Sartor RB,Tennyson GS,Riddell RH.Experimental models of inflammatory bowel disease.Gastroenterology 1995;109:1344-67.
[77] Bobin-Dubigeon C,Collin X,Grimaud N,Robert JM,Le Baut G,Petit JY.Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis.Eur J Pharmacol 2001;431:103-10.
[78] Van Klinken BJ,Dekker J,Buller HA,Einerhand AW.Mucin gene structure and expression:protection vs.adhesion.Am J Physiol 1995;269:G613-27.
[79] Gendler SJ,Spicer AP.Epithelial mucin genes.Annu Rev Physiol 1995;57:607-34.
[80] Tytgat KM,Buller HA,Opdam FJ,Kim YS,Einerhand AW,Dekker J.Biosynthesis of human colonic mucin:Muc2 is the prominent secretory mucin.Gastroenterology 1994;107:1352-63.
[81] McCormick DA,Horton LW,Mee AS.Mucin depletion in inflammatory bowel disease.J Clin Pathol 1990;43:143-6.
[82] Shaoul R,Okada Y,Cutz E,Marcon MA.Colonic expression of MUC2,MUC5AC,and TFF1 in inflammatory bowel disease in children.J Pediatr Gastroenterol Nutr 2004;38:488-93.
[83] Loncar MB,Al-azzeh ED,Sommer PS,Marinovic M,Schmehl K,Kruschewski M,Blin N,Stohwasser R,Gott P,Kayademir T.Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide.Gut 2003;52:1297-303.
[84] Enss ML,Cornberg M,Wagner S,Gebert A,Henrichs M,Eisenblatter R,Beil W,Kownatzki R,Hedrich HJ.Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180.Inflamm Res 2000;49:162-9.
[85] Lin J,Nadroo AM,Chen W,Holzman IR,Fan QX,Babyatsky MW.Ontogeny and prenatal expression of trefoil factor 3/ITF in the human intestine.Early Hum Dev 2003;71:103-9.
[86] Yu K,Jiang SF,Lin MF,Wu JB,Lin J.Extraction and purification of biologically active intestinal trefoil factor from human meconium.Lab Invest 2004;84:390-2.
[87] Blanchard C,Durual S,Estienne M,Bouzakri K,Heim MH,Blin N,Cuber JC.IL-4 and IL-13 up-regulate intestinal trefoil factor expression:requirement for STAT6 and de novo protein synthesis.J Immunol 2004;172:3775-83.
[88] Dignass A,Lynch-Devaney K,Kindon H,Thim L,Podolsky DK.Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway.J Clin Invest 1994;94:376-83.
[89] Kinoshita K,Taupin DR,Itoh H,Podolsky DK.Distinct pathways of cell migration and antiapoptotic response to epithelial injury:structure-function analysis of human intestinal trefoil factor.Mol Cell Biol 2000;20:4680-90.
[90] Podolsky DK.Mechanisms of regulatory peptide action in the gastrointestinal tract:trefoil peptides.J Gastroenterol 2000;35 Suppl 12:69-74.
[91] Tran CP,Cook GA,Yeomans ND,Thim L,Giraud AS.Trefoil peptide TFF2(spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis.Gut 1999;44:636-42.
[92] Itoh H,Tomita M,Uchino H,Kobayashi T,Kataoka H,Sekiya R,Nawa Y.cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis.Biochem J 1996;318(Pt 3):939-44.
[93] Tomita M,Itoh H,Ishikawa N,Higa A,Ide H,Murakumo Y,Maruyama H,Koga Y,Nawa Y.Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes.Biochem J 1995;311(Pt 1):293-7.
[94] Ogata H,Podolsky DK.Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine.Am J Physiol 1997;273:G348-54.
[95] Gardiner KR,Halliday MI,Barclay GR,Milne L,Brown D,Stephens S,Maxwell RJ,Rowlands BJ.Significance of systemic endotoxaemia in inflammatory bowel disease.Gut 1995;36:897-901.
[96] Jung HC,Eckmann L,Yang SK,Panja A,Fierer J,Morzycka-Wroblewska E,Kagnoff MF.A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.J Clin Invest 1995;95:55-65.
[97] Gibson P,Rosella O.Interleukin 8 secretion by colonic crypt cells in vitro:response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.Gut 1995;37:536-43.
[98] Geppert TD,Whitehurst CE,Thompson P,Beutler B.Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway.Mol Med 1994;1:93-103.
[99] Su C,Salzberg BA,Lewis JD,Deren JJ,Kornbluth A,Katzka DA,Stein RB,Adler DR,Lichtenstein GR.Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.Am J Gastroenterol 2002;97:2577-84.
[100] Komatsu M,Kobayashi D,Saito K,Furuya D,Yagihashi A,Araake H,Tsuji N,Sakamaki S,Niitsu Y,Watanabe N.Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR.Clin Chem 2001;47:1297-301.
[101] Masuda H,Iwai S,Tanaka T,Hayakawa S.Expression of IL-8,TNF-alpha and IFN-gamma m-RNA in ulcerative colitis,particularly in patients with inactive phase.J Clin Lab Immunol 1995;46:111-23.
[102] Akazawa A,Sakaida I,Higaki S,Kubo Y,Uchida K,Okita K.Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,particularly in patients with disease in the inactive phase.J Gastroenterol 2002;37:345-53.
[103] Stevens C,Walz G,Singaram C,Lipman ML,Zanker B,Muggia A,Antonioli D,Peppercorn MA,Strom TB.Tumor necrosis factor-alpha,interleukin-1 beta,and interleukin-6 expression in inflammatory bowel disease.Dig Dis Sci 1992;37:818-26.
[104] Sawa Y,Oshitani N,Adachi K,Higuchi K,Matsumoto T,Arakawa T.Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.Int J Mol Med 2003;11:175-9.
[105] Gisbert JP,Gonzalez-Lama Y,Mate J.Systematic review:Infliximab therapy in ulcerative colitis.Aliment Pharmacol Ther 2007;25:19-37.
[106] Lawson MM,Thomas AG,Akobeng AK.Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.Cochrane Database Syst Rev 2006;3:CD005112.
[107] Rutgeerts P,Sandborn WJ,Feagan BG,Reinisch W,Olson A,Johanns J,Travers S,Rachmilewitz D,Hanauer SB,Lichtenstein GR,de Villiers WJ,Present D,Sands BE,Colombel JF.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med 2005;353:2462-76.
[108] McAlindon ME,Hawkey CJ,Mahida YR.Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease.Gut 1998;42:214-9.
[109] Mahida YR,Wu K,Jewell DP.Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.Gut 1989;30:835-8.
[110] Ligumsky M,Simon PL,Karmeli F,Rachmilewitz D.Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.Gut 1990;31:686-9.
[111] Saiki T,Mitsuyama K,Toyonaga A,Ishida H,Tanikawa K.Detection of pro-and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease.Scand J Gastroenterol 1998;33:616-22.
[112] Daig R,Andus T,Aschenbrenner E,Falk W,Scholmerich J,Gross V.Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.Gut 1996;38:216-22.
[113] Ina K,Kusugami K,Yamaguchi T,Imada A,Hosokawa T,Ohsuga M,Shinoda M,Ando T,Ito K,Yokoyama Y.Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease.Am J Gastroenterol 1997;92:1342-6.
[114] Keshavarzian A,Fusunyan RD,Jacyno M,Winship D,MacDermott RP, Sanderson IR.Increased interleukin-8(IL-8)in rectal dialysate from patients with ulcerative colitis:evidence for a biological role for IL-8 in inflammation of the colon.Am J Gastroenterol 1999;94:704-12.
[115] Descoteaux A,Matlashewski G.Regulation of tumor necrosis factor gene expression and protein synthesis in murine macrophages treated with recombinant tumor necrosis factor.J Immunol 1990;145:846-53.
[116] Nawroth PP,Bank I,Handley D,Cassimeris J,Chess L,Stern D.Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.J Exp Med 1986;163:1363-75.
[117] Casellas F,Papo M,Guarner F,Antolin M,Armengol JR,Malagelada JR.Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.Clin Sci(Lond)1994;87:453-8.
[118] Sangfelt P,Carlson M,Thorn M,Xu S,Loof L,Raab Y.Local release of human neutrophil lipocalin(HNL),IL-8,and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis.Dig Dis Sci 2002;47:2064-9.
[119] Dinarello CA.Interleukin-1 and its biologically related cytokines.Adv Immunol 1989;44:153-205.
[120] Di Giovine FS,Duff GW.Interleukin 1:the first interleukin.Immunol Today 1990;11:13-20.
[121] Aggarwal BB,Natarajan K.Tumor necrosis factors:developments during the last decade.Eur Cytokine Netw 1996;7:93-124.
[122] Van Hogezand RA,Verspaget HW.Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality? Neth J Med 1996;48:64-7.
[1]Van Klinken BJ,Dekker J,Buller HA,Einerhand AW.Mucin gene structure and expression:protection vs.adhesion.Am J Physiol 1995;269:G613-27.
[2]Gendler SJ,Spicer AP.Epithelial mucin genes.Annu Rev Physiol 1995;57:607-34.
[3]Kim YS,Gum J,Jr.,Brockhausen I.Mucin glycoproteins in neoplasia.Glycoconj J 1996;13:693-707.
[4] Leikauf GD,Borchers MT,Prows DR,Simpson LG.Mucin apoprotein expression in COPD.Chest 2002;121:166S-182S.
[5] Tytgat KM,Bovelander FJ,Opdam FJ,Einerhand AW,Buller HA,Dekker J.Biosynthesis of rat MUC2 in colon and its analogy with human MUC2.Biochem J 1995;309(Pt 1):221-9.
[6] Tytgat KM,Buller HA,Opdam FJ,Kim YS,Einerhand AW,Dekker J.Biosynthesis of human colonic mucin:Muc2 is the prominent secretory mucin.Gastroenterology 1994;107:13 52-63.
[7] Williams SJ,McGuckin MA,Gotley DC,Eyre HJ,Sutherland GR,Antalis TM.Two novel mucin genes down-regulated in colorectal cancer identified by differential display.Cancer Res 1999;59:4083-9.
[8] Allen A,Hutton DA,Pearson JP.The MUC2 gene product:a human intestinal mucin.Int J Biochem Cell Biol 1998;30:797-801.
[9] Gum JR,Jr.,Hicks JW,Toribara NW,Rothe EM,Lagace RE,Kim YS.The human MUC2 intestinal mucin has cysteine-rich subdomains located both upstream and downstream of its central repetitive region.J Biol Chem 1992;267:21375-83.
[10] Gum JR,Jr.,Hicks JW,Toribara NW,Siddiki B,Kim YS.Molecular cloning of human intestinal mucin(MUC2)cDNA.Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor.J Biol Chem 1994;269:2440-6.
[11] Xu G,Huan LJ,Khatri IA,Wang D,Bennick A,Fahim RE,Forstner GG,Forstner JF.cDNA for the carboxyl-terminal region of a rat intestinal mucin-like peptide.J Biol Chem 1992;267:5401-7.
[12] Hansson GC,Baeckstrom D,Carlstedt I,Klinga-Levan K.Molecular cloning of a cDNA coding for a region of an apoprotein from the 'insoluble' mucin complex of rat small intestine. Biochem Biophys Res Commun 1994;198:181-90.
[13] Dekker J,Strous GJ.Covalent oligomerization of rat gastric mucin occurs in the rough endoplasmic reticulum,is N-glycosylation-dependent,and precedes initial O-glycosylation.J Biol Chem 1990;265:18116-22.
[14] Renes IB,Boshuizen JA,Van Nispen DJ,Bulsing NP,Buller HA,Dekker J,Einerhand AW.Alterations in Muc2 biosynthesis and secretion during dextran sulfate sodium-induced colitis.Am J Physiol Gastrointest Liver Physiol 2002;282:G382-9.
[15] Nieuw Amerongen AV,Bolscher JG,Bloemena E,Veerman EC.Sulfomucins in the human body.Biol Chem 1998;379:1-18.
[16] Julian J,Carson DD.Formation of MUCl metabolic complex is conserved in tumor-derived and normal epithelial cells.Biochem Biophys Res Commun 2002;293:1183-90.
[17] Velcich A,Yang W,Heyer J,Fragale A,Nicholas C,Viani S,Kucherlapati R,Lipkin M,Yang K,Augenlicht L.Colorectal cancer in mice genetically deficient in the mucin Muc2.Science 2002;295:1726-9.
[18] Jass JR,Roberton AM.Colorectal mucin histochemistry in health and disease:a critical review.Pathol Int 1994;44:487-504.
[19] van Klinken BJ,Einerhand AW,Duits LA,Makkink MK,Tytgat KM,Renes IB,Verburg M,Buller HA,Dekker J.Gastrointestinal expression and partial cDNA cloning of murine Muc2.Am J Physiol 1999;276:G115-24.
[20] Tytgat KM,Buller HA,Einerhand AW,van Deventer SJ,Dekker J.[Role of mucins in inflammatory intestinal diseases],Ned Tijdschr Geneeskd 1994;138:2386-90.
[21] McCormick DA,Horton LW,Mee AS.Mucin depletion in inflammatory bowel disease.J Clin Pathol 1990;43:143-6.
[22] Shaoul R,Okada Y,Cutz E,Marcon MA.Colonic expression of MUC2,MUC5AC,and TFF1 in inflammatory bowel disease in children.J Pediatr Gastroenterol Nutr 2004;38:488-93.
[23] Renes IB,Verburg M,Van Nispen DJ,Taminiau JA,Buller HA,Dekker J,Einerhand AW.Epithelial proliferation,cell death,and gene expression in experimental colitis:alterations in carbonic anhydrase I,mucin MUC2,and trefoil factor 3 expression.Int J Colorectal Dis 2002;17:317-26.
[24] Hanski C,Born M,Foss HD,Marowski B,Mansmann U,Arasteh K,Bachler B,Papenfuss M,Niedobitek F.Defective post-transcriptional processing of MUC2 mucin in ulcerative colitis and in Crohn's disease increases detectability of the MUC2 protein core.J Pathol 1999;188:304-11.
[25] Van Klinken BJ,Van der Wal JW,Einerhand AW,Buller HA,Dekker J.Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis.Gut 1999;44:387-93.
[26] Jacobs LR,Huber PW.Regional distribution and alterations of lectin binding to colorectal mucin in mucosal biopsies from controls and subjects with inflammatory bowel diseases.J Clin Invest 1985;75:112-8.
[27] Pullan RD,Thomas GA,Rhodes M,Newcombe RG,Williams GT,Allen A,Rhodes J.Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.Gut 1994;35:353-9.
[28] Theodossi A,Spiegelhalter DJ,Jass J,Firth J,Dixon M,Leader M,Levison DA,Lindley R,Filipe I,Price A,et al.Observer variation and discriminatory value of biopsy features in inflammatory bowel disease.Gut 1994;35:961-8.
[29] Tytgat KM,van der Wal JW,Einerhand AW,Buller HA,Dekker J.Quantitative analysis of MUC2 synthesis in ulcerative colitis.Biochem Biophys Res Commun 1996;224:397-405.
[30] Morita H,Kettlewell MG,Jewell DP,Kent PW.Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects.Gut 1993;34:926-32.
[31] Clamp JR,Fraser G,Read AE.Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. Clin Sci (Lond)1981;61:229-34.
[32] Feizi T,Gooi HC,Childs RA,Picard JK,Uemura K,Loomes LM,Thorpe SJ,Hounsell EF.Tumour-associated and differentiation antigens on the carbohydrate moieties of mucin-type glycoproteins.Biochem Soc Trans 1984;12:591-6.
[33] Parker N,Tsai HH,Ryder SD,Raouf AH,Rhodes JM.Increased rate of sialylation of colonic mucin by cultured ulcerative colitis mucosal explants.Digestion 1995;56:52-6.
[34] Raouf AH,Tsai HH,Parker N,Hoffman J,Walker RJ,Rhodes JM.Sulphation of colonic and rectal mucin in inflammatory bowel disease:reduced sulphation of rectal mucus in ulcerative colitis.Clin Sci(Lond)1992;83:623-6.
[35] Roediger WE,Moore J,Babidge W.Colonic sulfide in pathogenesis and treatment of ulcerative colitis.Dig Dis Sci 1997;42:1571-9.
[36] Corfield AP,Myerscough N,Bradfield N,Corfield Cdo A,Gough M,Clamp JR,Durdey P,Warren BF,Bartolo DC,King KR,Williams JM.Colonic mucins in ulcerative colitis:evidence for loss of sulfation.Glycoconj J 1996;13:809-22.
[37] Weiss AA,Babyatsky MW,Ogata S,Chen A,Itzkowitz SH.Expression of MUC2 and MUC3 mRNA in human normal,malignant,and inflammatory intestinal tissues.J Histochem Cytochem 1996;44:1161-6.
[38] Ni J,Chen SF,Hollander D.Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes.Gut 1996;39:234-41.
[39]Faure M,Moennoz D,Montigon F,Mettraux C,Mercier S,Schiffiin EJ,Obled C,Breuille D,Boza J.Mucin production and composition is altered in dextran sulfate sodium-induced colitis in rats.Dig Dis Sci 2003;48:1366-73.
[40]Thim L.A new family of growth factor-like peptides.'Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide(pS2),pancreatic spasmolytic polypeptide(PSP),and frog skin peptides(spasmolysins).FEBS Lett 1989;250:85-90.
[41]Suemori S,Lynch-Devaney K,Podolsky DK.Identification and characterization of rat intestinal trefoil factor:tissue-and cell-specific member of the trefoil protein family.Proc Natl Acad Sci U S A 1991;88:11017-21.
[42]Thim L.Trefoil peptides:from structure to function.Cell Mol Life Sci 1997;53:888-903.
[43]Taupin DR,Pang KC,Green SP,Giraud AS.The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut.Peptides 1995;16:1001-5.
[44]Podolsky DK,Lynch-Devaney K,Stow JL,Oates P,Murgue B,De-Beaumont M,Sands BE,Mahida YR.Identification of human intestinal trefoil factor.Goblet cell-specific expression of a peptide targeted for apical secretion.J Biol Chem 1993;268:12230.
[45]Taupin D,Pedersen J,Familari M,Cook G,Yeomans N,Giraud AS.Augmented intestinal trefoil factor(TFF3)and loss of pS2(TFF1)expression precedes metaplastic differentiation of gastric epithelium.Lab Invest 2001;81:397-408.
[46] Wong WM,Poulsom R,Wright NA.Trefoil peptides.Gut 1999;44:890-5.
[47]Poulsom R,Hanby AM,Lalani EN,Hauser F,Hoffmann W,Stamp GW.Intestinal trefoil factor(TFF 3)and pS2(TFF 1),but not spasmolytic polypeptide(TFF 2)mRNAs are co-expressed in normal,hyperplastic,and neoplastic human breast epithelium.J Pathol 1997;183:30-8.
[48] dos Santos Silva E,Ulrich M,Doring G,Botzenhart K,Gott P.Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000;190:133-42.
[49] Kindon H,Pothoulakis C,Thim L,Lynch-Devaney K,Podolsky DK.Trefoil peptide protection of intestinal epithelial barrier function:cooperative interaction with mucin glycoprotein.Gastroenterology 1995;109:516-23.
[50] Wright NA,Pike C,Elia G Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells.Nature 1990;343:82-5.
[51] Alison MR,Chinery R,Poulsom R,Ashwood P,Longcroft JM,Wright NA.Experimental ulceration leads to sequential expression of spasmolytic polypeptide,intestinal trefoil factor,epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach.J Pathol 1995;175:405-14.
[52] Dignass A,Lynch-Devaney K,Kindon H,Thim L,Podolsky DK.Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway.J Clin Invest 1994;94:376-83.
[53] Chinery R,Playford RJ.Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat.Clin Sci(Lond)1995;88:401-3.
[54] Babyatsky MW,deBeaumont M,Thim L,Podolsky DK.Oral trefoil peptides protect against ethanol-and indomethacin-induced gastric injury in rats.Gastroenterology 1996;110:489-97.
[55] Beck PL,Wong JF,Li Y,Swaminathan S,Xavier RJ,Devaney KL,Podolsky DK.Chemotherapy-and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor.Gastroenterology 2004;126:796-808.
[56] Efstathiou JA,Noda M,Rowan A,Dixon C,Chinery R,Jawhari A,Hattori T,Wright NA,Bodmer WF,Pignatelli M.Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells.Proc Natl Acad Sci U S A 1998;95:3122-7.
[57] Yamachika T,Werther JL,Bodian C,Babyatsky M,Tatematsu M,Yamamura Y,Chen A,Itzkowitz S.Intestinal trefoil factor:a marker of poor prognosis in gastric carcinoma.Clin Cancer Res 2002;8:1092-9.
[58] Kanai M,Mullen C,Podolsky DK.Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells.Proc Natl Acad Sci U S A 1998;95:178-82.
[59] Wright NA,Poulsom R,Stamp GW,Hall PA,Jeffery RE,Longcroft JM,Rio MC,Tomasetto C,Chambon P.Epidermal growth factor(EGF/URO)induces expression of regulatory peptides in damaged human gastrointestinal tissues.J Pathol 1990;162:279-84.
[60] Gronbaek H,Vestergaard EM,Hey H,Nielsen JN,Nexo E.Serum trefoil factors in patients with inflammatory bowel disease.Digestion 2006;74:33-9.
[61] Feng ZM,Fang DC,Chen WS,Wang RQ.Rodent IRR-219(IgGFcgammaBP)and rTFF3,Expressed Mainly in the Intestinal Mucosa,Depleted During Dextran Sulfate Sodium-Induced Colitis.Dig Dis Sci 2007.
[62] Tomita M,Itoh H,Ishikawa N,Higa A,Ide H,Murakumo Y,Maruyama H,Koga Y,Nawa Y.Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes.Biochem J 1995;311(Pt 1):293-7.
[63] Itoh H,Tomita M,Uchino H,Kobayashi T,Kataoka H,Sekiya R,Nawa Y.cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis.Biochem J I996;318(Pt 3):939-44.
[64] Mashimo H,Wu DC,Podolsky DK,Fishman MC.Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.Science 1996;274:262-5.
[65]Dossinger V,Kayademir T,Blin N,Gott P.Down-regulation of TFF expression in gastrointestinal cell lines by cytokines and nuclear factors.Cell Physiol Biochem 2002;12:197-206.
[66]Baus-Loncar M,Al-azzeh ED,Romanska H,Lalani el N,Stamp GW,Blin N,Kayademir T.Transcriptional control of TFF3(intestinal trefoil factor)via promoter binding sites for the nuclear factor kappaB and C/EBPbeta.Peptides 2004;25:849-54.
[67]Loncar MB,Al-azzeh ED,Sommer PS,Marinovic M,Schmehl K,Kruschewski M,Blin N,Stohwasser R,Gott P,Kayademir T.Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide.Gut 2003;52:1297-303.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |